NL-OMON23532招募中不适用
Phase I/II trial of Lenalidomide plus Bortezomib combined with Dexamethasone in patients in 1st relapse or primary refractory after first line therapy for Multiple Myeloma.
Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON)P/a HOVON Data CenterErasmus MC - Daniel den HoedPostbus 52013008 AE RotterdamTel: 010 7041560Fax: 010 70410280 个研究点目标入组 72 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 72
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Multiple Myeloma Salmon/Durie stage II/III A+B
- •2. Primary refractory to or first relapse after previous objective response (PR, VGPR, CR) on standard first-line treatment
排除标准
- •1. Prior therapy with Bortezomib or Lenalidomide
- •2. History of allergic reaction attributable to compounds containing boron or mannitol
研究者
相似试验
进行中（未招募）
不适用
Phase I/II trial of Lenalidomide plus Bortezomib combined with Dexamethasone in elderly patients in 1st relapse or primary refractory after first line therapy for Multiple Myeloma - HOVON 86 MMMedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomamultiple myelomaEUCTR2007-002533-37-NLHOVON Foundation84
进行中（未招募）
1 期
Phase I/II trial of Lenalidomide plus Bortezomib combined with Dexamethasone in elderly patients in 1st relapse or primary refractory after first line therapy for Multiple Myeloma - HOVON 86 MMMedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomamultiple myelomaEUCTR2007-002533-37-BEHOVON Foundation84
已完成
2 期
Phase I/II trial of Lenalidomide plus Bortezomib combined with Dexamethasone in elderly patients in 1st relapse or primary refractory after first line therapy for multiple myeloma.Kahlers disease10035227multiple myelomaNL-OMON33820HOVO68
已完成
1 期
Phase I/II study of bortezomib plus Lenalidomide and dexamethasone (Once weekly VRd-21) for relapsed and/or refractory multiple myeloma (Once weekly VRd-21, I/II VRD for MM)Proteasome inhibitor and immunomodulatory drug pre-treated relapsed and/or refractory multiple myeloma after two or more prior lines of chemotherapyJPRN-UMIN000013169agoya City University Hospital30
终止
2 期
Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell TransplantRefractory Plasma Cell MyelomaNCT02353468University of Colorado, Denver3